These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 27855998)

  • 1. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.
    Carter BA; Cohran VC; Cole CR; Corkins MR; Dimmitt RA; Duggan C; Hill S; Horslen S; Lim JD; Mercer DF; Merritt RJ; Nichol PF; Sigurdsson L; Teitelbaum DH; Thompson J; Vanderpool C; Vaughan JF; Li B; Youssef NN; Venick RS; Kocoshis SA
    J Pediatr; 2017 Feb; 181():102-111.e5. PubMed ID: 27855998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.
    Lambe C; Talbotec C; Kapel N; Barbot-Trystram L; Brabant S; Nader EA; Pigneur B; Payen E; Goulet O
    Am J Clin Nutr; 2023 Jun; 117(6):1152-1163. PubMed ID: 37270289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
    Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B
    Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.
    Wales PW; Hill S; Robinson I; Raphael BP; Matthews C; Cohran V; Carter B; Venick R; Kocoshis S
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):290-300. PubMed ID: 38873891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study.
    Germán-Díaz M; Alcolea A; Cabello V; Blasco-Alonso J; Rodríguez A; Galera R; García-Romero R; Romero C; González-Sacristán R; Redecillas-Ferreiro S; Moreno-Villares JM; Ramos-Boluda E
    Eur J Pediatr; 2024 Aug; 183(8):3173-3182. PubMed ID: 38664251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
    Kocoshis SA; Merritt RJ; Hill S; Protheroe S; Carter BA; Horslen S; Hu S; Kaufman SS; Mercer DF; Pakarinen MP; Venick RS; Wales PW; Grimm AA
    JPEN J Parenter Enteral Nutr; 2020 May; 44(4):621-631. PubMed ID: 31495952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
    Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
    Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
    Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
    Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure.
    Fifi A; Raphael BP; Terreri B; Uddin S; Kaufman SS
    J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):666-671. PubMed ID: 37889619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.
    Seidner DL; Fujioka K; Boullata JI; Iyer K; Lee HM; Ziegler TR
    Nutr Clin Pract; 2018 Aug; 33(4):520-527. PubMed ID: 29761915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.
    Hill S; Carter BA; Cohran V; Horslen S; Kaufman SS; Kocoshis SA; Mercer DF; Merritt RJ; Pakarinen MP; Protheroe S; Thompson JF; Vanderpool CPB; Venick RS; Wales PW; Smith SE; Yoon M; Grimm AA
    JPEN J Parenter Enteral Nutr; 2021 Sep; 45(7):1456-1465. PubMed ID: 33305440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.
    Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):45S-52S. PubMed ID: 24615689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.
    Ukleja A; To C; Alvarez A; Lara LF
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):821-825. PubMed ID: 29603279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.
    O'Keefe SJ; Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):815-23.e1-3. PubMed ID: 23333663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
    Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ
    Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.
    Lam K; Schwartz L; Batisti J; Iyer KR
    JPEN J Parenter Enteral Nutr; 2018 Jan; 42(1):225-230. PubMed ID: 29505151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
    Chiba M; Masumoto K; Kaji T; Matsuura T; Morii M; Fagbemi A; Hill S; Pakarinen MP; Protheroe S; Urs A; Chen ST; Sakui S; Udagawa E; Wada M
    J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):339-346. PubMed ID: 37364133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
    Kochar B; Long MD; Shelton E; Young L; Farraye FA; Yajnik V; Herfarth H
    J Clin Gastroenterol; 2017 Jul; 51(6):508-511. PubMed ID: 27433811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
    Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
    Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome.
    Gattini D; Belza C; Kraus R; Avitzur Y; Ungar WJ; Wales PW
    Clin Nutr; 2023 Dec; 42(12):2363-2371. PubMed ID: 37862822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.